Cathie Wood’s Top 5 Stock Picks

3. CRISPR Therapeutics AG (NASDAQ: CRSP)

Value: $1,594,331,000
Change in Position Size: 23%
Percent of  Cathie Wood’s 13F Portfolio: 4.2%

Crispr Therapeutics is a Swiss company which is working on technologies to make genome editing easier and faster. The company’s CRISPR-Cas9 is based on RNA-guided targeting. The technology can modify DNA with greater precision as compared to the existing solutions in the market. The stock is one of the top holdings of Cathie Wood’s ARK Innovation ETF (NYSEARCA:ARKK) as the fund is betting that the shares of the biotech company will post big gains as early as 2021.

As of the end of the fourth quarter, there were 34 hedge funds in Insider Monkey’s database that held stakes in CRISPR Therapeutics, compared to 26 funds in the third quarter. ARK is the company’s biggest stakeholder, with 10.4 million shares worth $1.6 billion.